[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

(2015) G. Gebhart et al.   ANNALS OF ONCOLOGY

89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients

(2014) S. B. M. Gaykema et al.   CLINICAL CANCER RESEARCH

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Using 64Cu-DOTA-Trastuzumab PET

(2013) J. E. Mortimer et al.   JOURNAL OF NUCLEAR MEDICINE

Routine Production of 89Zr Using an Automated Module

(2013) A. Wooten et al.   Applied Sciences-Basel

Quantitative Proteomics with siRNA Screening Identifies Novel Mechanisms of Trastuzumab Resistance in HER2 Amplified Breast Cancers

(2012) Alaina P. Boyer et al.   MOLECULAR & CELLULAR PROTEOMICS

p95HER2 and Breast Cancer

(2011) J. Arribas et al.   CANCER RESEARCH

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

(2011) Siyuan Zhang et al.   NATURE MEDICINE

Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer

(2010) E C Dijkers et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Molecular imaging of HER2-positive breast cancer: a step toward an individualized ‘image and treat’ strategy

(2010) Jacek Capala et al.   CURRENT OPINION IN ONCOLOGY

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

(2010) Howard A. Burris et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules

(2010) R. P. Baum et al.   JOURNAL OF NUCLEAR MEDICINE

Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine

(2010) Maria J W D Vosjan et al.   Nature Protocols

Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neuAmplification

(2009) Matteo Brunelli et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Standardized methods for the production of high specific-activity zirconium-89

(2009) Jason P. Holland et al.   NUCLEAR MEDICINE AND BIOLOGY

HER-2/neu expression in primary and metastatic breast cancer

(2008) Elyse E. Lower et al.   BREAST CANCER RESEARCH AND TREATMENT

Immunoscintigraphy as Potential Tool in the Clinical Evaluation of HER2/neu Targeted Therapy

(2008) Eli Dijkers et al.   CURRENT PHARMACEUTICAL DESIGN